The proportion of patients who had UACR reduced at least 50% from baseline to endpoint was 24.7% and 12.5% for Riprazo and placebo, respectively.
Patsientide hulk, kellel albumiini ja kreatiniini suhe uriinis vähenes algpunktist lõpp- punktini vähemalt 50% ’ i võrra, oli Riprazo korral 24, 7% ja platseebo korral 12, 5%.